Regeneron quarterly profit drops as COVID antibody sales hit (US.REGN) - 04 mai 2022

De la TradeVille.ro wiki


The drugmaker's net profit in the first quarter ended March 31 fell to $974 million, or $8.61 per share, from $1.12 billion, or $10.09 per share, a year earlier.

Its blockbuster eye treatment Eylea and eczema therapy Dupixent, however, performed well, recording sales growth of 11% and 43%, respectively.

Gradual easing of lockdowns amid increasing vaccinations has boded well for physician-administered eye treatment Eylea over the last few quarters.

Sales of Dupixent also helped Regeneron's overall sales grow 17% to $2.97 billion.


https://finance.yahoo.com/news/1-regeneron-quarterly-profit-drops-105006852.html?.tsrc=fin-srch

Adus de la „https://wiki.tradeville.ro/index.php?title=Regeneron_quarterly_profit_drops_as_COVID_antibody_sales_hit_(US.REGN)_-_04_mai_2022&oldid=5442”